Terms: = Prostate cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2
99 results:
1. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
2. The Value of the prostate Health Index and Derived Indexes in the Diagnosis of prostate cancer with PI-RADS-3 Lesions.
Cui Y; Zhao J; Sun Y
Urol Int; 2023; 107(10-12):959-964. PubMed ID: 38011845
[TBL] [Abstract] [Full Text] [Related]
3. Association of triglyceride-glucose index with the risk of prostate cancer: a retrospective study.
Li T; Zhou Y; Wang J; Xiao S; Duan Y; Li C; Gao Y; An H; Tao N
PeerJ; 2023; 11():e16313. PubMed ID: 37953784
[TBL] [Abstract] [Full Text] [Related]
4. [18F]FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake.
Nieri A; Manco L; Bauckneht M; Urso L; Caracciolo M; Donegani MI; Borgia F; Vega K; Colella A; Ippolito C; Cittanti C; Morbelli S; Sambuceti G; Turra A; Panareo S; Bartolomei M
Expert Rev Med Devices; 2023; 20(12):1183-1191. PubMed ID: 37942630
[TBL] [Abstract] [Full Text] [Related]
5. Oligometastatic prostate cancer Treated with Stereotactic Body Radiation Therapy: The Role of Three-Dimensional Tumour Volume in Patient Survival.
Franzese C; Lucchini R; Roghi M; Badalamenti M; Baldaccini D; Comito T; Franceschini D; Navarria P; Di Cristina L; Lo Faro L; Galdieri C; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e649-e656. PubMed ID: 37775459
[TBL] [Abstract] [Full Text] [Related]
6. Dose-Intensified Postoperative Radiation Therapy for prostate cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.
Li HZ; Qi X; Gao XS; Li XM; Qin SB; Li XY; Ma MW; Bai Y; Chen JY; Ren XY; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):697-705. PubMed ID: 37717784
[TBL] [Abstract] [Full Text] [Related]
7. Integrated Network Analysis to Determine CNN1, MYL9, TAGLN, and SORBS1 as Potential Key Genes Associated with prostate cancer.
Li C; Pang L; Jin F; Song Y; Zhou D; Song Y; Li Y; Jin S; Zhang L; Liang W; Shen X; Li J; She B; Wang C; Ma L
Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436378
[TBL] [Abstract] [Full Text] [Related]
8. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.
Zou BZ; Wen H; Luo HJ; Luo WC; Xie QT; Zhou MT
Ir J Med Sci; 2023 Dec; 192(6):2681-2687. PubMed ID: 37414978
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of CDKL3 downregulates STAT1 thus suppressing prostate cancer development.
Jiang Q; Li J; Wang J; Zhang W
Cell Death Dis; 2023 Mar; 14(3):189. PubMed ID: 36899018
[TBL] [Abstract] [Full Text] [Related]
10. Acute heart failure presentation, management, and outcomes in cancer patients: a national longitudinal study.
Coles B; Welch CA; Motiwale RS; Teece L; Oliver-Williams C; Weston C; de Belder MA; Lambert PC; Rutherford MJ; Paley L; Kadam UT; Lawson CA; Deanfield J; Peake MD; McDonagh T; Sweeting MJ; Adlam D;
Eur Heart J Acute Cardiovasc Care; 2023 May; 12(5):315-327. PubMed ID: 36888552
[TBL] [Abstract] [Full Text] [Related]
11. Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies.
Garcia L; Pearce M; Abbas A; Mok A; Strain T; Ali S; Crippa A; Dempsey PC; Golubic R; Kelly P; Laird Y; McNamara E; Moore S; de Sa TH; Smith AD; Wijndaele K; Woodcock J; Brage S
Br J Sports Med; 2023 Aug; 57(15):979-989. PubMed ID: 36854652
[TBL] [Abstract] [Full Text] [Related]
12. Staging accuracy of MRI of the prostate with special reference to the influence of the time of last ejaculation on the detection of seminal vesicle invasion.
Blasi F; Malouhi A; Cho CH; Nißler D; Berger FP; Grimm MO; Abubrig M; Teichgräber U; Franiel T
Clin Radiol; 2023 May; 78(5):e425-e432. PubMed ID: 36849278
[TBL] [Abstract] [Full Text] [Related]
13. A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant prostate cancer.
Xie W; Xu Z; Qiu Y; Ye W; Zhang Z; Wang C; Zang J
Biomed Res Int; 2023; 2023():9936087. PubMed ID: 36685670
[TBL] [Abstract] [Full Text] [Related]
14. PI-RADS
Yu R; Jiang KW; Bao J; Hou Y; Yi Y; Wu D; Song Y; Hu CH; Yang G; Zhang YD
Br J Cancer; 2023 Apr; 128(6):1019-1029. PubMed ID: 36599915
[TBL] [Abstract] [Full Text] [Related]
15. A pilot study of MRI radiomics for high-risk prostate cancer stratification in 1.5 T MR-guided radiotherapy.
Zhou Y; Yuan J; Xue C; Poon DMC; Yang B; Yu SK; Cheung KY
Magn Reson Med; 2023 May; 89(5):2088-2099. PubMed ID: 36572990
[TBL] [Abstract] [Full Text] [Related]
16. Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis.
Panunzio A; Barletta F; Tappero S; Cano Garcia C; Piccinelli M; Incesu RB; Law KW; Tian Z; Tafuri A; Tilki D; De Cobelli O; Chun FKH; Terrone C; Briganti A; Saad F; Shariat SF; Bourdeau I; Cerruto MA; Antonelli A; Karakiewicz PI
J Surg Oncol; 2023 Mar; 127(4):560-567. PubMed ID: 36434748
[TBL] [Abstract] [Full Text] [Related]
17. The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the prostate (TURP).
Liu J; Pan S; Dong L; Wu G; Wang J; Wang Y; Qian H; Dong B; Pan J; Zhu Y; Xue W
Curr Oncol; 2022 Sep; 29(9):6373-6382. PubMed ID: 36135071
[TBL] [Abstract] [Full Text] [Related]
18. A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients.
Dai T; Xu Z; Huang L; Wang Y; Zeng G; Ye M; Liu K; Zeng F; Jiang S; Han W; Cao J
Br J Clin Pharmacol; 2023 Feb; 89(2):874-886. PubMed ID: 36098470
[TBL] [Abstract] [Full Text] [Related]
19. Financial Toxicity and Its Association With prostate and Colon cancer Screening.
Herriges MJ; Shenhav-Goldberg R; Peck JI; Bhanvadia SK; Morgans A; Chino F; Chandrasekar T; Shapiro O; Jacob JM; Basnet A; Bratslavsky G; Goldberg H
J Natl Compr Canc Netw; 2022 Sep; 20(9):981-988. PubMed ID: 36075394
[TBL] [Abstract] [Full Text] [Related]
20. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
[TBL] [Abstract] [Full Text] [Related]
[Next]
